Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.

Saved in:
Bibliographic Details
Title: Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
Authors: Bautista F; Hospital Niño Jesús, Department of Pediatric Oncology, Hematology and Stem Cell Transplantation, Madrid, Spain., Paoletti X; Gustave Roussy Cancer Campus, Biostatistics and Epidemiology Unit, INSERM U1018, CESP, Université Paris-Saclay, UVSQ, Villejuif, France.; Current address: Institut Curie, INSERM U900 STAMPM, UVSQ, St Cloud, France., Rubino J; Gustave Roussy Cancer Campus, Clinical Research Direction, Villejuif, France., Brard C; Gustave Roussy Cancer Campus, Biostatistics and Epidemiology Unit, INSERM U1018, CESP, Université Paris-Saclay, UVSQ, Villejuif, France., Rezai K; Institut Curie, Radio-Pharmacology Department, Saint Cloud, France., Nebchi S; Gustave Roussy Cancer Campus, Biostatistics and Epidemiology Unit, INSERM U1018, CESP, Université Paris-Saclay, UVSQ, Villejuif, France., Andre N; Department of Pediatric Oncology, Hôpital de la Timone, AP-HM, Marseille, France.; UMR Inserm 1068, CNRS UMR 7258, Aix Marseille Université U105, Marseille Cancer Research Center (CRCM), Marseille, France., Aerts I; SIREDO Oncology Center (Care, Innovation and research for children and AYA with cancer), Institut Curie, PSL Research University, Paris, France., De Carli E; Department of Pediatric Oncology, University Hospital, Angers, France., van Eijkelenburg N; Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands., Thebaud E; Department of Pediatric Oncology, Centre Hospitalier Universitaire, Nantes, France., Corradini N; Pediatric Oncology Department, Institut of Pediatric Hematology and Oncology, Centre Leon Berard, Lyon, France., Defachelles AS; Department of Pediatric Oncology, Oscar Lambret Cancer Center, Lille, France., Ducassou S; Centre Hospitalier Universitaire Pellegrin-Hôpital des Enfants, Bordeaux, France., Morscher RJ; Gustave Roussy Cancer Campus, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France.; INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France., Vassal G; Gustave Roussy Cancer Campus, Clinical Research Direction, Villejuif, France., Geoerger B; Gustave Roussy Cancer Campus, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France.; INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Nov 10; Vol. 39 (32), pp. 3546-3560. Date of Electronic Publication: 2021 Aug 04.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Adaptive Clinical Trial
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO.21.01152